Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A Stewart1, Patrick G Pilié2, Timothy A Yap3
1Pfizer Global Product Development, Pfizer, La Jolla, California. ross.a.stewart@pfizer.com.
Abstract:
PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
What is the Immune System?
Humoral Immune Responses
Dipeptidyl Peptidase 4 Inhibitors
Sustainable Development


